Walleye Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.82M | Buy |
6,037
+281
| +5% | +$84.8K | ﹤0.01% | 1920 |
|
|
2026
Q1 | $1.9M | Sell |
5,756
-2,901
| -34% | -$987K | ﹤0.01% | 1746 |
|
|
2025
Q4 | $3.44M | Buy |
8,657
+7,062
| +443% | +$3.13M | ﹤0.01% | 1525 |
|
|
2025
Q3 | $727K | Buy |
1,595
+1,252
| +365% | +$510K | ﹤0.01% | 2482 |
|
|
2025
Q2 | $112K | Sell |
343
-3,017
| -90% | -$835K | ﹤0.01% | 3541 |
|
|
2025
Q1 | $907K | Buy |
+3,360
| New | +$864K | ﹤0.01% | 2118 |
|
|
2024
Q3 | – | Sell |
-1,318
| Closed | -$343K | – | 4066 |
|
|
2024
Q2 | $320K | Sell |
1,318
-23,854
| -95% | -$3.77M | ﹤0.01% | 2803 |
|
|
2024
Q1 | $3.76M | Buy |
25,172
+2,661
| +12% | +$444K | 0.01% | 1321 |
|
|
2023
Q4 | $4.31M | Buy |
+22,511
| New | +$3.83M | 0.01% | 1332 |
|
|
2023
Q3 | – | Sell |
-4,489
| Closed | -$856K | – | 4961 |
|
|
2023
Q2 | $853K | Sell |
4,489
-1,548
| -26% | -$307K | ﹤0.01% | 2322 |
|
|
2023
Q1 | $1.21M | Buy |
+6,037
| New | +$1.27M | ﹤0.01% | 2054 |
|
|
2022
Q4 | – | Sell |
-28,223
| Closed | -$6.02M | – | 4926 |
|
|
2022
Q3 | $5.65M | Buy |
28,223
+16,154
| +134% | +$3.08M | 0.02% | 951 |
|
|
2022
Q2 | $1.76M | Buy |
+12,069
| New | +$1.71M | 0.01% | 1774 |
|
|
2022
Q1 | – | Sell |
-3,305
| Closed | -$504K | – | 5262 |
|
|
2021
Q4 | $560K | Buy |
3,305
+1,705
| +107% | +$317K | ﹤0.01% | 2840 |
|
|
2021
Q3 | $302K | Sell |
1,600
-651
| -29% | -$122K | ﹤0.01% | 3447 |
|
|
2021
Q2 | $382K | Buy |
2,251
+1,597
| +244% | +$234K | ﹤0.01% | 3245 |
|
|
2021
Q1 | $92K | Sell |
654
-765
| -54% | -$115K | ﹤0.01% | 4135 |
|
|
2020
Q4 | $184K | Buy |
+1,419
| New | +$189K | ﹤0.01% | 3578 |
|
|
2020
Q2 | – | Sell |
-11,048
| Closed | -$1.49M | – | 4203 |
|
|
2020
Q1 | $1.2M | Buy |
+11,048
| New | +$1.28M | 0.01% | 1175 |
|
|
2019
Q4 | – | Sell |
-2,986
| Closed | -$298K | – | 4202 |
|
|
2019
Q3 | $240K | Sell |
2,986
-34
| -1% | -$2.69K | ﹤0.01% | 2798 |
|
|
2019
Q2 | $219K | Buy |
+3,020
| New | +$232K | ﹤0.01% | 2874 |
|
|
2019
Q1 | – | Sell |
-5,236
| Closed | -$438K | – | 4127 |
|
|
2018
Q4 | $382K | Sell |
5,236
-3,967
| -43% | -$305K | ﹤0.01% | 2758 |
|
|
2018
Q3 | $805K | Buy |
9,203
+4,589
| +99% | +$462K | ﹤0.01% | 2341 |
|
|
2018
Q2 | $454K | Buy |
+4,614
| New | +$458K | ﹤0.01% | 2938 |
|
|
2015
Q4 | – | Sell |
-300
| Closed | -$24K | – | 5232 |
|
|
2015
Q3 | $24K | Buy |
300
+200
| +200% | +$22.2K | ﹤0.01% | 3962 |
|
|
2015
Q2 | $12K | Buy |
+100
| New | +$11.9K | ﹤0.01% | 4223 |
|
Other funds holding ALNY
Walleye Trading's ALNY Position: Q2 2026 in Review
Walleye Trading increased its Alnylam Pharmaceuticals (ALNY) stake by 4.9% in Q2 2026, buying an estimated $84.8K and bringing the position to 6,037 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1920.
Walleye Trading first reported a position in ALNY in Q2 2015 and has held it in 26 quarters since. The position peaked at $5.65M in Q3 2022. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Walleye Trading held 6,037 shares of Alnylam Pharmaceuticals worth $1.82M as of Q2 2026.
- Walleye Trading bought 281 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $84.8K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #1920 holding.
- Walleye Trading first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 26 quarters since.
- Walleye Trading's Alnylam Pharmaceuticals position peaked at $5.65M in Q3 2022.
- 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.